Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | EVP & General Manager US | July 16, 2025 | July 17, 2025 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 16, 2025 · Filed July 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,149 |
Reported balance
After 2025-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-07-16 · Sale · Disposed 1,340 · Balance 35,149 F1: This includes an aggregate of 35,136 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This includes an aggregate of 35,136 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 1
1 source rowRow 1 · 2019-11-08 · Disposition to issuer · Disposed 397 · Balance 0 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $10,989 and 178 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.20 · Expires 2029-04-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $13,463 and 220 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $10,989 and 178 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $13,463 and 220 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2019 Filed Nov 14, 2019 21:45 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Disposition to issuerCommon Stock | 397 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-056641 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $10,989 and 178 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:01 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 185 | $67.28 | $12,446.80 |
DisclosureSEC source: 0001209191-19-052459 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 20:30 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 2,491 | $77.71 | $193,575.61 |
DisclosureSEC source: 0001209191-19-050234 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,757 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 17, 2019 Filed Jul 18, 2019 22:13 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 959 | $79.91 | $76,633.69 |
DisclosureSEC source: 0001209191-19-042668 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,248 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 20:42 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 430 | $81.39 | $34,997.70 |
DisclosureSEC source: 0001209191-19-042173 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,207 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 13,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:34 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 273 | $85.28 | $23,281.44 |
DisclosureSEC source: 0001209191-19-041565 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,637 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 15,340 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:35 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040898 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F4 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:35 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 417 | $85.01 | $35,449.17 |
DisclosureSEC source: 0001209191-19-040898 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,910 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 16,219 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:35 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040898 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,327 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Barry Flannelly's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:50 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 212 | $58.86 | $12,478.32 |
DisclosureSEC source: 0001209191-19-041249 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 19:27 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantDirector Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $65.20 | $0.00 |
DisclosureSEC source: 0001209191-19-025296 · doc4.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 0 shares Expires 2029-04-16 F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on April 16, 2020, and becomes exercisable as to 1/48th of the shares each full month thereafter. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 22:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 5,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011191 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,333 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 14, 2019. The performance shares vest 25% annually over four years from the grant date of July 2, 2018, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of revenue-based performance criteria determined by the Issuer's Compensation Committee in February 2018 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 150% of the number of performance shares awarded, and the performance criteria was achieved at the 83% level. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to the performance shares reported above and previously reported restricted stock units that have not vested as of February 14, 2019. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 21:22 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,000 | $80.00 | $80,000.00 |
DisclosureSEC source: 0001209191-19-006004 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,944 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:11 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,714 | $75.56 | $129,509.84 |
DisclosureSEC source: 0001209191-19-003251 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,944 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:16 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 896 | $74.21 | $66,492.16 |
DisclosureSEC source: 0001209191-19-002767 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,658 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:16 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 63,105 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002767 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,105 Underlying: Common Stock · 63,105 shares Expires 2029-01-03 F4 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in full on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:16 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002767 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2029-01-03 F3 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 20:23 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,000 | $70.00 | $70,000.00 |
DisclosureSEC source: 0001209191-18-054382 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,427 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:09 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 430 | $70.19 | $30,181.70 |
DisclosureSEC source: 0001209191-18-043025 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,427 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 20:49 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 273 | $68.28 | $18,640.44 |
DisclosureSEC source: 0001209191-18-041702 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,857 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:49 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041702 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2028-07-01 F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:10 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,026 | $86.03 | $88,266.78 |
DisclosureSEC source: 0001209191-18-012338 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,823 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 10,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:31 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,128 | $0.00 Strike: $94.63 | $0.00 |
DisclosureSEC source: 0001209191-18-005382 · doc4.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,128 Underlying: Common Stock · 12,128 shares Expires 2028-01-22 F1 · derivative.exercise_date: Beginning January 23, 2018, options become exercisable in 37 installments, with the first 25.00% vesting on July 5, 2018 and the remainder vesting monthly over three years. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 20:11 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 714 | $124.25 | $88,714.50 |
DisclosureSEC source: 0001209191-17-052954 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,782 F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · balance_after: Includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:11 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 674 | $123.15 | $83,003.10 |
DisclosureSEC source: 0001209191-17-052954 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,496 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:03 UTC | INCYTE CORP INCY · Entity 3182 | GrantIncentive Stock Option (right to buy) · Derivative | 779 | $0.00 Strike: $128.34 | $0.00 |
DisclosureSEC source: 0001209191-17-044427 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779 Underlying: Common Stock · 779 shares Expires 2027-07-04 F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:03 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,349 | $0.00 Strike: $128.34 | $0.00 |
DisclosureSEC source: 0001209191-17-044427 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,349 Underlying: Common Stock · 11,349 shares Expires 2027-07-04 F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:03 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 3,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044427 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,170 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Flannelly's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 01, 2017 Filed May 2, 2017 22:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,064 | $0.00 Strike: $48.44 | $0.00 |
DisclosureSEC source: 0001209191-17-029346 · doc4.xml · derivative · entry 4 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,720 Underlying: Common Stock · 2,064 shares Expires 2021-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning August 11, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| May 01, 2017 Filed May 2, 2017 22:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 4,493 | $124.75 | $560,501.75 |
DisclosureSEC source: 0001209191-17-029346 · doc4.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,653 F1 · price: Reporting person undertakes to provide upon request by Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F2 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $123.92 - $125.47. F5 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 01, 2017 Filed May 2, 2017 22:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 803 | $124.61 | $100,061.83 |
DisclosureSEC source: 0001209191-17-029346 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,146 F1 · price: Reporting person undertakes to provide upon request by Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F2 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $123.97 - $125.38. Read SEC document |
| May 01, 2017 Filed May 2, 2017 22:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 2,064 | $48.44 | $99,980.16 |
DisclosureSEC source: 0001209191-17-029346 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:48 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,473 | $121.95 | $301,582.35 |
DisclosureSEC source: 0001209191-17-015327 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,743 F3 · shares: Represents shares withheld to satisfy tax withholding obligations with respect to vested performance shares. F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 14, 2017 Filed Feb 28, 2017 21:48 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-015327 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,216 F1 · shares: Represents shares acquired upon vesting of performance shares. Each performance share represented the right to receive one or more shares of common stock based on, and subject to, the achievement of certain clinical and revenue milestones as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 125% of the number of performance shares awarded. Performance share milestones were achieved at the 100% level. F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:35 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,091 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004506 · doc4.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,091 Underlying: Common Stock · 19,091 shares Expires 2027-01-16 F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:33 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 21,796 | $0.00 Strike: $48.44 | $0.00 |
DisclosureSEC source: 0001209191-16-145577 · doc4.xml · derivative · entry 5 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,422 Underlying: Common Stock · 21,796 shares Expires 2021-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning August 11, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:33 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,408 | $0.00 Strike: $48.44 | $0.00 |
DisclosureSEC source: 0001209191-16-145577 · doc4.xml · derivative · entry 4 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,784 Underlying: Common Stock · 2,408 shares Expires 2021-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning August 11, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:33 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 24,204 | $97.00 | $2,347,788.00 |
DisclosureSEC source: 0001209191-16-145577 · doc4.xml · nonDerivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,187 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:33 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 21,796 | $48.44 | $1,055,798.24 |
DisclosureSEC source: 0001209191-16-145577 · doc4.xml · nonDerivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:33 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 2,408 | $48.44 | $116,643.52 |
DisclosureSEC source: 0001209191-16-145577 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.